Insilico Medicine Cayman Topco Says Collaboration Grants Lilly Exclusive Worldwide License for Development, Manufacturing and Commercialization of Oral Therapeutics in Preclinical Development
Bff Banking Group - in Addition, Bank Has Initiated Analysis on Ancillary Credit Rights Payments Between 2015 and 2025 Totaling €452M
Bff: Receives Bank of Italy Regulatory Measure
Bff Banking Group - Bank of Italy Appoints Raffaele Lener and Francesco Fioretto as Commissioners to Bff
Bff Banking Group - Bank of Italy Findings Could Result in Additional Past Due Exposure of up to €0.8Bn
Insilico Medicine Cayman Topco Announces Licensing and Drug Discovery Collaboration With Eli Lilly
Insilico Medicine Cayman Topco 2025 Revenue $56.2 Mln
Hansoh Pharmaceutical 2025 Profit Attributable to Owners of Parent at 5.56 Bln Yuan
Hansoh Pharmaceutical Group Company FY Revenue RMB 15,028 Million
Kuwait Projects FY Bonus Share 3%
Kipco Qtrly Attributable Net Profit 2.9 Mln Dinars
Greenland Hong Kong Holdings FY Revenue RMB 12,322 Million
Lilly Will Acquire Exclusive Rights to Sell a Glp-1 Drug for Diabetes From Insilico Medicine - FT
Eli Lilly to Sign $2Bn Deal for AI Drug Development With Hong Kong Biotech Insilico Medicine - FT
Samsung Biologics Union Votes 95.5% in Favour of Strike Action, First in Company’s History -Media